Genmab revenue and financials

GMAB · NASDAQ · USD

Secondary listing. The primary listing is Genmab · Nasdaq Copenhagen (DKK)

$37.80Change from previous close: −1.77%Absolute change: −$0.68

Close · October 6, 2026

In the fiscal year ended December 2025, Genmab reported revenue of kr 3.72B (+19.19% year over year). Net income was kr 963M, a net margin of 25.9%.

Annual revenue · 2025: kr 3.72B
  1. kr 2.37B2017
  2. kr 3.03B2018
  3. kr 5.37B2019
  4. kr 2.39B2023
  5. kr 3.12B2024
  6. kr 3.72B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth
+19.19%
2025 vs 2024
Net income growth
−87.72%
2025 vs 2024
Net margin
25.9%
2024: 251.3%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Balance sheet · Quarterly
ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total assets12,51512,37612,8737,0216,4646,5866,4145,9325,5495,3055,2334,998
Current assets2,8012,5732,8854,4713,9104,0373,9003,5443,1524,9714,9144,684
Cash and equivalents1,5031,5211,7151,7611,2961,6191,3809496222,1222,2052,024
Short-term investments——0.01,6501,6031,6071,574—1,6382,1571,9681,880
Receivables1,2731,0271,1521,046998799937944886677734770
Inventory18.021.018.014.013.012.09.010.65.215.38.59.9
Net property, plant and equipment254265280266277271265269270269243234
Goodwill355355355355355355355360362———
Other intangible assets8,8728,9489,1231,7481,7521,7561,7281,7211,7263.315.016.3
Long-term investments39.041.037.036.035.030.032.028.328.222.119.922.1
Current liabilities1,1401,1781,427741629756744686627399368412
Long-term debt4,8414,9335,001—————————
Total debt5,2735,3515,426142148———————
Total liabilities6,5586,6947,0261,2701,1621,2901,2771,1571,099605546585
Total equity (incl. minority)5,9575,6825,8475,7515,3025,2965,1374,7744,4494,7004,6884,413
Retained earnings4,4214,0904,0984,0323,5983,5373,3922,9352,6052,8642,8212,617